MHE Question of the Week: Health Insurance Coverage of GLP-1s for Weight Loss
Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss.
The glucagon-like peptide 1 (GLP-1) drugs is a class that includes now-famous Ozempic (semaglutide) and Mounjaro (tirzepatide), which were approved by the FDA as diabetes treatments but have been used off-label for weight loss. After FDA approvals, on-label versions are available for weight, marketed under the names Wegovy (semaglutide) and Zepbound (tirzepatide). Prescriptions of the GLP-1s have soared as patients and prescribers have flocked to a pharmaceutical answer to the U.S. obesity epidemic. The cost has strained insurer budgets. There are also questions about the long-term outcomes of GLP-1s and how long people are sticking with the treatments, which are administered as injections.
Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss.
Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss
We want to know what you’re thinking! Every Monday morning the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. Answers will be published every Friday.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
